DUPONT CAPITAL MANAGEMENT Corp bought a new position in Halyard Health Inc (NYSE:HYH) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 7,900 shares of the medical instruments supplier’s stock, valued at approximately $301,000.
Several other institutional investors have also made changes to their positions in HYH. CENTRAL TRUST Co raised its position in shares of Halyard Health by 1.0% in the first quarter. CENTRAL TRUST Co now owns 2,643 shares of the medical instruments supplier’s stock worth $101,000 after buying an additional 25 shares during the period. WFG Advisors LP raised its position in shares of Halyard Health by 107.8% in the fourth quarter. WFG Advisors LP now owns 2,747 shares of the medical instruments supplier’s stock worth $334,000 after buying an additional 1,425 shares during the period. Glen Harbor Capital Management LLC raised its position in shares of Halyard Health by 1.1% in the first quarter. Glen Harbor Capital Management LLC now owns 3,230 shares of the medical instruments supplier’s stock worth $123,000 after buying an additional 34 shares during the period. Capstone Asset Management Co. acquired a new position in shares of Halyard Health during the first quarter worth about $203,000. Finally, Creative Planning raised its position in shares of Halyard Health by 17.1% in the first quarter. Creative Planning now owns 5,679 shares of the medical instruments supplier’s stock worth $216,000 after buying an additional 830 shares during the period. Institutional investors and hedge funds own 87.50% of the company’s stock.
Shares of Halyard Health Inc (NYSE:HYH) opened at 36.20 on Friday. The company’s 50 day moving average price is $37.66 and its 200 day moving average price is $37.93. Halyard Health Inc has a one year low of $29.07 and a one year high of $41.84. The firm has a market capitalization of $1.69 billion, a P/E ratio of 44.09 and a beta of 1.87.
Halyard Health (NYSE:HYH) last issued its quarterly earnings results on Tuesday, May 2nd. The medical instruments supplier reported $0.48 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.43 by $0.05. Halyard Health had a return on equity of 8.63% and a net margin of 2.80%. The business had revenue of $395.60 million during the quarter, compared to the consensus estimate of $391.56 million. During the same period in the previous year, the business earned $0.53 EPS. The business’s quarterly revenue was up 2.8% on a year-over-year basis. On average, analysts expect that Halyard Health Inc will post $1.85 EPS for the current fiscal year.
WARNING: This piece was first published by sleekmoney and is the property of of sleekmoney. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://sleekmoney.com/dupont-capital-management-corp-takes-position-in-halyard-health-inc-hyh/1838312.html.
A number of equities analysts have recently issued reports on the stock. Zacks Investment Research lowered shares of Halyard Health from a “buy” rating to a “hold” rating in a research report on Thursday, May 4th. Stephens lowered shares of Halyard Health from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, February 28th. Stifel Nicolaus raised their target price on shares of Halyard Health from $38.00 to $45.00 and gave the stock a “buy” rating in a research report on Tuesday, February 28th. Finally, TheStreet lowered shares of Halyard Health from a “b-” rating to a “c” rating in a research report on Wednesday, May 3rd. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $40.50.
About Halyard Health
Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.
Want to see what other hedge funds are holding HYH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halyard Health Inc (NYSE:HYH).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/dupont-capital-management-corp-takes-position-in-halyard-health-inc-hyh/1838312.html
Receive News & Ratings for Halyard Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.